Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487585 · ClinicalTrials.gov registry record · Phase 4
ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
A Phase 4 study of Vasodilatory Hypotension During or After Cardiac Surgery, sponsored by University of Maryland St. Joseph Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06487585: Recruiting Phase 4 study of Vasodilatory Hypotension During or After Cardiac Surgery, sponsored by University of Maryland St. Joseph Medical Center.
NCT06487585 is a Phase 4 study of Vasodilatory Hypotension During or After Cardiac Surgery that is actively recruiting participants, run by University of Maryland St. Joseph Medical Center. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487585, a Phase 4 study of Vasodilatory Hypotension During or After Cardiac Surgery, is actively recruiting participants, sponsored by University of Maryland St. Joseph Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
Primary Outcome
The primary endpoint will be measured by comparing the incidence of new-onset atrial fibrillation or acute kidney injury
Conditions Studied
Interventions
- DRUG Angiotensin II
Study Locations (1)
Maryland
- University of Maryland St. Joseph Medical Center - Towson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
What NCT06487585 shows while recruiting
NCT06487585 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Vasodilatory Hypotension During or After Cardiac Surgery appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II is the first listed.
NCT06487585 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06487585 about?
NCT06487585 is a clinical study titled "ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)". The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
What is the current status of trial NCT06487585?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-05-06. Estimated completion is 2026-02.
What conditions does trial NCT06487585 study?
This clinical trial studies the following conditions: Vasodilatory Hypotension During or After Cardiac Surgery.
What interventions are being tested in trial NCT06487585?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT06487585?
This trial is sponsored by University of Maryland St. Joseph Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487585 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06487585's enrollment target sits among peer trials
100 770th of 2000 higher than 1,149 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI